Rebecca P. Bystrom

Also affiliated with United States Food and Drug Administration, Center for Drug Evaluation and Research, National Heart Lung and Blood Institute, Duke Medical Center

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML”.

Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML

Blood Advances(2024)10.1182/bloodadvances.2024012858

N/A

0DataRank · unranked

12 citations

Shai Shimony, Rory M. Shallis, Yiwen Liu, Guillaume Berton, Eva J. Schaefer +18 more

Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1‐ or IDH2‐mutant newly diagnosed acute myeloid leukemia—A multicenter cohort study

American Journal of Hematology(2024)10.1002/ajh.27366

N/A

0DataRank · unranked

9 citations

Shai Shimony, Rory M. Shallis, Yiwen Liu, Guillaume Berton, Eva J. Schaefer +18 more